headwind collabor cut
page full analyst note dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
walgreen one success retail oper
sinc found remain major player within
pharmaceut suppli chain mani decad firm
process approxim total prescript
fiscal make one largest retail pharmaci
acquisit europe-bas allianc boot firm
premier global retail powerhous nevertheless believ
walgreen face pressur oper environ given
rapidli grow price power larg pharmaci benefit
manag pbm abl aggreg enorm amount
claim volum leverag power price negoti
walgreen tri off-set headwind drive sale volum
consolid sell nonnpharmaceut
product opinion demonstr weaker posit
along pharmaceut suppli chain walgreen tri
counter pressur retail pharmaci oper environ
cosmet groceri household conveni good
strategi also put firm even direct competit
vast array retail sector profit outsiz
return invest capit hard come
posit note firm recent acquir half
store fleet solidifi walgreen largest retail
pharmaci chain acquisit increas
volum geograph reach also materi augment
global gener purchas volum walgreen also
better-posit build prefer pharmaci strategi
strategi entail retail pharmaci discount gener drug
inventori becom prefer pharmaci pbm retail network
drive store foot traffic
strategi promis walgreen yet report
improv same-stor compar result front-end
product addit firm struggl compress
gross margin last hand year believ
trend directli reflect steep headwind face pharmaci
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
walgreen nation largest retail pharmaci approxim
drugstor throughout unit state firm recent acquir
half locat increas store count scale
larg network store enabl firm reach signific portion
 popul provid excel brand recognit prescript
drug account two third sale balanc attribut
front-stor product groceri health beauti item
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
headwind collabor dec
walgreen boot allianc report result first
quarter fiscal novemb
consist expect expect
signific chang valuat overal firm top
line increas heavili driven store
acquisit march growth exclud
closer constant currenc bottom
line gross margin pressur counter strong
benefit tax reform adjust tax rate fell
allow adjust net earn
growth share repurchas drove adjust ep growth
even higher given tailwind tax reform
quarter annual start calendar
continu tailwind billion expect share
repurchas fiscal year think adjust
ep growth guidanc constant currenc full fiscal
year reason new cost-cut program
save billion annual expect three
year also help counter persist headwind
firm face see share fairli valu
continu see competit landscap pharmaci
busi consolid competitor drug price
weak uncertainti surround retail growth
contribut lack econom moat
verili healthcar subsidiari alphabet
focus use technolog reduc cost improv
care patient chronic condit walgreen
start small pilot project improv medic
adher partnership sanofi diabet
manag walgreen employe potenti
benefit walgreen bottom line like
appar near term build walgreen prior
collabor firm includ
aim increas conveni
dive quarter result top-lin strength
pharmaci busi counter continu weak
retail intern pharmaci pharmaci
gross margin continu see reimburs contract
pressur pharmaci busi sale growth
translat organ growth exclud
rite-aid acquisit gross margin divis
basi point due specialti shift dilut
januari
compar pharmaci growth
prescript share retail sale
compar basi de-emphasi tobacco
strong first quarter fiscal attribut
hurrican strong cold/flu season even
adjust currenc headwind account chang
divestitur sale walgreen
pharmaci segment declin organ
 walgreen cite strong rel perform
overal weaken retail pharmaci market
expect trend revers near term
walgreen saw hit adjust oper
margin quarter adjust oper incom
pressur largest retail pharmaci segment
basi point also intern retail
pharmaci basi point distribut
basi point larg due currenc impact
emerg market growth remain strong despit
continu cost-cut improv sg
percentag sale exist retail pharmaci
segment sg pressur retail pharmaci
larg due
fair valu estim walgreen
factor acquisit approxim rite aid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pharmaci strategi shift demograph
increas pharmaceut usag healthcar benefit
payer flat prescript drug price offset dynam
gener becom greater percentag prescript
fill payer look way hold overal cost
employe benefit check also project firm
sale front-stor product nonpharmaceut good
grow line overal growth mix
averag oper margin rang
explicit forecast
scenario analysi take consider effect
custom supplier price negoti leverag
overal demand use pharmaceut product
prefer pharmaci strategi success walgreen
front-end product sale strategi bull-cas scenario
factor less price profit pressur due
custom price demand increas supplier price
leverag addit factor acceler growth
prescript front-stor product assum
success front-stor sale strategi scenario
fair valu estim increas
bear case assum firm face even price
pressur drug benefit plan payer alreadi
order preserv prefer pharmaci posit
addit assum secular trend boost
secular pharmaceut demand strong
initi believ firm front-stor strategi fail
boost nonprescript product sale averag
growth scenario fair valu estim
decreas
obtain moat retail pharmaci industri extrem
tough believ walgreen
possess econom moat confluenc price
store walgreen acquir total number
store initi sought action allow
firm move larger store count also
particip sourc remain gener inventori
wbad partnership ad volum
lucr joint ventur lower gener cost given
circumst believ correct cours
action think firm like reap
value-cr synergi deal howev remain
cautiou firm success integr asset
network given underinvest natur
rite aid store asset overal action modestli
posit dcf valuat also believ firm
continu produc solid long-term valu gener
sourc joint ventur boast
express script member
perspect recent strateg partnership
walgreen close allow gain greater
distribut effici enhanc manufactur price
leverag ultim lead increas profit
next year forecast adjust prescript
increas moder driven firm prefer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
firm may possess competit advantag
consist produc econom profit believ
remain key player within healthcar space
player along pharmaceut suppli
chain signific leverag walgreen
believ enough valu firm vast network
retail locat ensur stabl moat trend firm
extens retail footprint conveni locat throughout
unit state recogn brand prime
distribut channel solid variabl keep
econom moat stabl addit around store
acquir also expand geograph
market reach area littl presenc
addit market share help least stem
pressur major pharmaci custom drug benefit plan
mass grocer retail heavi depend
nonpharmaceut front-stor product profit
steadili push firm return invest capit
downward fact roic adjust oper leas
steadili fallen toward firm adjust weight averag
cost capit past five year
forese signific recoveri metric believ
return remain trajectori
off-set aforement headwind
walgreen sought enhanc supplier
purchas power acquir allianc boot major
retail distributor
partner amerisourcebergen
pharmaceut distributor purchas half rite
aid retail locat opportun gain distribut
effici enhanc manufactur price leverag
relationship posit walgreen
howev partnership direct respons
price pressur firm face larg payer
opinion walgreen need off-set price pressur
lower reimburs rate payer build
supplier negoti power potenti gain better
manufactur price said total
convinc strateg move abl significantli
chang long-term trajectori firm abil
produc consist econom profit roic
posit influenc tactic believ
effici gain off-set price power drug
plan payer variabl consum discretionari
believ walgreen stabl moat trend even though
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
owalgreen largest retail pharmaci
network give firm abil reach
excel scale
opharmaceut spend grow solidli
next sever year given demograph shift
expans medic coverag mani uninsur
individu drive demand walgreen core back-
orec partnership potenti provid
improv result retail pharmaci
oth confluenc price pressur greater
competit mass grocer retail
heavi depend nonpharmaceut product
profit steadili push roic downward
owalgreen contend payer client base
signific price power thank power
posit major pbm
oth firm face increas direct competit
mass grocer retail believ
advantag reli conveni mild
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
walgreen oper decent level financi leverag
firm debt-to-ebitda ratio end
fiscal even though use signific portion
cash balanc acquisit approxim
store believ firm need
issu new debt believ firm abl rebuild
cash balanc without problem sinc assum
debt deal
main risk face walgreen price pressur
prescript benefit payer retail custom supplier
pharmaceut product even though firm struck
partnership tone player along drug
suppli chain anoth contract disput major pbm
could caus contract top- bottom-lin
result effect oligopoli firm
variabl even heighten given focu
mani drug plan payer significantli curb overal
narrow pharmaci network
addit signific portion walgreen result
depend consum discretionari spend
fluctuat materi econom cycl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/director/vic chairman
repres date owner name posit common share held report holder issuer
share
fund
share
fund
stefano pessina firm major sharehold
ceo execut vice chairman sinc januari
posit undoubtedli given iron grip
firm perspect everi aspect
oper strategi driven pessina larg
view mani current sharehold compet
retail given earlier turnaround allianc boot
busi believ extens success
histori oper europ largest retail pharmaci
posit asset view pessina larg
european manag team underestim
nuanc healthcar retail market firm
struggl perform better part
last sever year retrench year-over-year
comp highlight firm struggl specif
concern firm strategi tri push sale
health beauti product given dynam
 consum skeptic strategi
nevertheless also believ certain strateg move
execut last year ad posit
walgreen long-term outlook notabl rite aid
acquisit enhanc firm overal retail oper
built effici distribut capabl
addit firm effect
manufactur price negoti power use
combin demand major retail firm
integr partnership also give
walgreen prime posit along pharmaceut
suppli chain move help bolster
distribut effici supplier negoti leverag
firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pharmaceut industri entiti better known
 resid retail pharmaci combin
special personnel need essenti core product
one might think firm posit consist
produc econom profit howev believ walgreen
face steep long-term headwind struggl
margin compress firm discount drug
inventori order drive store traffic tri
drive front-stor sale off-set profit pressur
result last sever quarter indic
strategi yet show inde preserv grow
profit walgreen perspect firm
long-term profit outlook remain uncertain see long-
term challeng ahead retail pharmaci signific
consolid among major pharmaci variou
shift strategi away core pharmaceut sale
major retail chain underscor tighten oper
walgreen report mix headwind continu
pressur oper oct
walgreen report mix fourth quarter integr
acquisit formul new strategi
incorpor sever move part even
tumultu oper environ firm result fall
line analysi reiter no-moat
rate fair valu estim firm struggl
cope rapidli chang pharmaceut market
pressur reimburs massiv consolid
increas competit prescript volum firm
basic sought two-prong strategi build scale
acquir partner drug suppli
chain player also tri drive nonpharma sale
particularli cosmet larg posit regard
firm effort build scale acquisit
exampl joint ventur help firm obtain
lower gener price preserv least materi
portion gross profit also believ firm
partnership mass retailers/supermarket
acquisit help scale oper
howev posit walgreen
nonpharma sale strategi backfil lower level
pharmaceut profit manag tri increas
sale front-of-the-stor nonpharma product howev
front-stor sale continu drag same-stor
sale categori fall manag mention
ration promot strategi start
de-emphas cigarett sale weigh
neg last quarter trend
concern fall line outlook
product particular cosmet believ manag
would better serv invest creat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end august
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end august
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
